A new trading day began on Friday, with Ionis Pharmaceuticals Inc (NASDAQ: IONS) stock price up 0.11% from the previous day of trading, before settling in for the closing price of $35.59. IONS’s price has ranged from $33.33 to $54.44 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 13.97%. Meanwhile, its annual earnings per share averaged -36.79%. With a float of $145.55 million, this company’s outstanding shares have now reached $157.81 million.
Considering the fact that the conglomerate employs 927 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 97.3%, operating margin of -46.11%, and the pretax margin is -44.29%.
Ionis Pharmaceuticals Inc (IONS) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Ionis Pharmaceuticals Inc is 7.82%, while institutional ownership is 98.05%. The most recent insider transaction that took place on Nov 12 ’24, was worth 45,278. In this transaction EVP Research of this company sold 1,194 shares at a rate of $37.92, taking the stock ownership to the 33,713 shares. Before that another transaction happened on Nov 12 ’24, when Company’s Chief Executive Officer sold 6,630 for $38.05, making the entire transaction worth $252,294. This insider now owns 167,393 shares in total.
Ionis Pharmaceuticals Inc (IONS) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.95 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -36.79% per share during the next fiscal year.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) Trading Performance Indicators
Here are Ionis Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 8.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.01.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.44, a number that is poised to hit -1.11 in the next quarter and is forecasted to reach -3.70 in one year’s time.
Technical Analysis of Ionis Pharmaceuticals Inc (IONS)
Compared to the last year’s volume of 1.36 million, its volume of 2.42 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 9.43%. Additionally, its Average True Range was 1.47.
During the past 100 days, Ionis Pharmaceuticals Inc’s (IONS) raw stochastic average was set at 12.58%, which indicates a significant increase from 11.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 36.64% in the past 14 days, which was lower than the 40.42% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $37.43, while its 200-day Moving Average is $41.93. Nevertheless, the first resistance level for the watch stands at $36.34 in the near term. At $37.04, the stock is likely to face the second major resistance level. The third major resistance level sits at $37.69. If the price goes on to break the first support level at $34.99, it is likely to go to the next support level at $34.34. Should the price break the second support level, the third support level stands at $33.64.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) Key Stats
With a market capitalization of 5.63 billion, the company has a total of 157,897K Shares Outstanding. Currently, annual sales are 787,650 K while annual income is -366,290 K. The company’s previous quarter sales were 133,810 K while its latest quarter income was -140,480 K.
